Avella | briovaRx Choose Location

Enzyme Replacement Therapy / Lysosomal Storage Disease Enrollment Form

Please detach before submitting to a pharmacy – tear here.

PATIENT INFORMATION

*Please complete the following or **send patient demographic sheet***

Patient Name _____

Address _____

Address 2 _____

City, State, ZIP _____

Home Phone _____ Alternate Phone _____

DOB _____ Last Four of SS# _____ Gender _____

Language Preference: ☐ English ☐ Spanish ☐ Other _____

PRESCRIBER INFORMATION

Prescriber's Name _____

DEA _____

NPI _____

Group / Hospital _____

Address _____

City, State, ZIP _____

Phone _____ Fax _____

Contact Person _____ Phone _____

INSURANCE INFORMATION *(Must fax a copy of patient's insurance card including both sides)*

Prior Authorization Reference number _____

MEDICAL INFORMATION ***(Section must be completed to process prescription)*** *(Please supply pertinent clinical data for prior authorizations. Attach separate sheet if needed)*

Diagnosis — *Please include diagnosis name with ICD-10 code*

☐ E74.00 Glycogen storage disease, unspecified ☐ E74.01 von Gierke disease

☐ E74.04 McArdle disease ☐ E74.09 Other glycogen storage disease _____

☐ E75.21 Fabry (-Anderson) disease ☐ E75.22 Gaucher disease

☐ E75.249 Niemann-Pick disease, unspecified ☐ E76.01 Hurler's Syndrome

☐ E76.03 Scheie's Syndrome ☐ E76.1 Mucopolysaccharidosis, type II

☐ E76.219 Morquio Mucopolysaccharidosis, unspecified ☐ E76.22 Sanfilippo Mucopolysaccharidosis

☐ E76.29 Other Mucopolysaccharidosis _____

☐ E76.3 Mucopolysaccharidosis, unspecified

☐ E77.0 Defects in post-translational modification of lysosomal enzymes

☐ E77.1 Defects in glycoprotein degradation

☐ Other Diagnosis: ICD-10 Code _____ Description _____

Date of Diagnosis _____

Start Date _____ **Review Date** _____ **Next Infusion Date** _____

Additional Information

Therapy: ☐ New ☐ Reauthorization ☐ Restart

Weight _____ kg / lbs

Height _____ cm / in

Allergies _____

Lab Data _____

Concomitant Medications _____

Additional Comments _____

PRESCRIPTION INFORMATION

Medication	Dose / Strength	Directions	Quantity	Refills
☐ Aldurazyme®	☐ 2.9mg Vial with Albumin	_____ mg/kg IV Body Weight Every _____ Days		
☐ Cerdelga®	☐ 84mg Capsule	☐ Once Daily ☐ Twice Daily		
☐ Cerezyme®	☐ 200 Unit Vial ☐ 400 Unit Vial	_____ Units/kg IV Body Weight Every _____ Days		
☐ Elaprase®	☐ 6mg Vial	_____ mg/kg IV Body Weight Every _____ Days		
☐ Fabrazyme®	☐ 5mg Vial ☐ 35mg Vial	_____ mg/kg IV Body Weight Every _____ Days		
☐ Lumizyme®	☐ 50mg Vial	_____ mg/kg IV Body Weight Every _____ Days		
☐ VPRIV®	☐ 200 Unit Vial ☐ 400 Unit Vial	_____ Units/kg IV Body Weight Every _____ Days		

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: ☐ Patient ☐ Office ☐ Other _____ Date _____ Needs by Date _____

☐ Product Substitution permitted ☐ Dispense as Written

Prescriber's Signature _____ Date _____

Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.